

CHRONOLOGY OF MAJOR ACTIVITIES DURING  
REGULATORY REVIEW. RELATING TO  
IND 17,123

Date

|                   |                   |  |
|-------------------|-------------------|--|
| January 10, 1980  | Submission to FDA | IND 17,123 for Sodium Phenylacetate                                    |
| January 24, 1980  | Letter from FDA   | Acknowledged receipt of IND 17,123                                     |
| February 19, 1980 | Submission to FDA | Amended IND 17,123   |
| March 17, 1980    | Submission to FDA | Amended IND 17,123   |
| March 17, 1980    | Letter from FDA   | Request for additional information                                     |
| March 21, 1980    | Submission to FDA | Response with requested information                                    |
| May 12, 1980      | Letter from FDA   | Acknowledgment of receipt of information and request regarding labels. |
| June 6, 1980      | Submission to FDA | Labels sent in response to request.                                    |
| June 13, 1980     | Submission to FDA | Amended IND 17,123   |
| August 18, 1980   | Submission to FDA | Amended IND 17,123   |
| May 7, 1981       | Submission to FDA | Annual Report  |
| April 12, 1982    | Submission to FDA | Annual Report  |
| Undated           | Letter from FDA   | Request for additional information                                     |
| June 8, 1982      | Submission to FDA | Response to request information  |
| November 3, 1982  | Submission to FDA | Amended IND 17,123   |
| February 2, 1983  | Submission to FDA | Amended IND 17,123   |

|                   |                   |   |
|-------------------|-------------------|---|
| May 24, 1983      | Submission to FDA | Annual Report                                       |
| November 28, 1983 | Submission to FDA | Amended IND 17,123                                  |
| July 23, 1984     | Letter from FDA   |   |
| August 7, 1984    | Submission to FDA | Amended IND 17,123                                  |
| August 9, 1984    | Submission to FDA | Amended IND 17,123                                  |
| February 26, 1986 | Letter from FDA   | Letter re combined<br>file IND 17,123<br>and 17,336 |

CHRONOLOGY OF MAJOR ACTIVITIES DURING  
REGULATORY REVIEW. RELATING TO  
IND 17,336

Date

|                   |                   |   |
|-------------------|-------------------|---|
| March 17, 1980    | Submission to FDA | IND 17,336 filed  |
| April 2, 1980     | Letter from FDA   | Letter of<br>acknowledgement                                    |
| February 12, 1981 | Letter from FDA   | Request for<br>additional<br>information                        |
| Undated           | Submission to FDA | Response to<br>request for<br>additional<br>information         |
| May 22, 1981      | Submission to FDA | Annual Report   |
| August 18, 1982   | Submission to FDA | Amended IND 17,336  |
| November 3, 1982  | Submission to FDA | Letter regarding<br>experimental<br>protocol                    |
| February 3, 1983  | Submission to FDA | Amended IND 17,336  |
| April 22, 1982    | Submission to FDA | Annual Report   |
| August 17, 1984   | Submission to FDA | Annual Report   |
| October 1, 1984   | Letter from FDA   | Notification that<br>IND transferred to<br>different department |
| February 26, 1986 | Letter from FDA   | Letter re combined<br>file IND 17,123 and<br>17,336             |

NDA 19-530

| DATE     | SUBJECT  | LOCATION |      |
|----------|--|----------|------|
|          |  | VOL.     | TAB  |
| 02/25/86 | Submitted samples and standards for Dallas and Atlanta.  | 1.1      | OR.1 |
| 07/16/86 | FDA letter requesting further clinical information.  | 1.1      | OR.1 |
| 09/04/86 | Submitted additional clinical information.   | 1.1      | OR.1 |
| 09/09/86 | Letter from FDA establishing a new due date of November 4, 1986.                                     | 1.1      | OR.1 |
| 10/13/86 | Letter to FDA informing them of our intent to exercise orphan drug exclusivity once NDA is approved. | 1.1      | OR.1 |
| 10/22/86 | FDA deficiency letter concerning clinical data and manufacturing and controls.                       | 1.1      | OR.1 |
| 08/14/87 | Submitted deficiency response to FDA letter of 10/22/86.   | 1.1      | OR.1 |
| 10/16/87 | FDA approvable letter for original application with request for further information.                 | 1.1      | OR.1 |
| 10/28/87 | Letter to FDA to inform them of intent to amend application by 11/13/87.                             | 1.1      | OR.1 |
| 11/12/87 | Submitted amendment to original application per FDA request in 10/16/87 approvable letter.           | 1.1      | OR.1 |
| 12/07/87 | Amendment to Chemistry, Manufacturing and Controls section.  | 1.1      | OR.1 |
| 12/23/87 | FDA approval of original application.  | 1.1      | OR.1 |
| 01/25/88 | Letter to FDA correcting typographical error (patent No.) in our August 1987 amendment.              | 1.1      | OR.1 |

INDEX

NDA 19-530

Ucephan Oral Liquid

| <u>DATE</u> | <u>SUBJECT</u>                                       | <u>LOCATION</u> |            |
|-------------|--|-----------------|------------|
|             |  | <u>VOL.</u>     | <u>TAB</u> |
| 01/26/88    | Letter from FDA granting seven years<br>exclusivity. | 1.1             | OR.1       |